Literature DB >> 2831608

Mode of action of the quinolone antimicrobial agents.

D C Hooper1, J S Wolfson.   

Abstract

The newer quinolone antimicrobial agents are more potent antibacterial agents than is the older analog nalidixic acid. For many of the quinolone agents, increased antibacterial potency correlates with increased potency in inhibiting the essential bacterial enzyme DNA gyrase. Studies with mutants resistant to drug action have identified the A subunit of this enzyme as a drug target. Other drug-resistance mutations are associated with pleiotropic drug resistance and decreased amounts of porin outer-membrane proteins and appear to involve alterations in permeability of the bacterium to the drug. Structure-activity studies of a large number of quinolone analogs have identified the importance to drug action of substituents at positions 1, 3, 4, 6, and 7 of the quinolone ring. Uncertainties remain, however, about the details of the molecular interactions of quinolones, DNA gyrase, and DNA and about the specific events that lead to quinolone-mediated bacterial killing.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2831608     DOI: 10.1093/clinids/10.supplement_1.s14

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  15 in total

1.  Use of in vitro topoisomerase II assays for studying quinolone antibacterial agents.

Authors:  J F Barrett; T D Gootz; P R McGuirk; C A Farrell; S A Sokolowski
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

Review 2.  In vitro assays used to measure the activity of topoisomerases.

Authors:  J F Barrett; J A Sutcliffe; T D Gootz
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

3.  Value of new quinolones in the treatment and prophylaxis of infectious diseases: introductory remarks.

Authors:  J S Wolfson; B E Murray
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-12       Impact factor: 3.267

4.  Mechanisms of clinical resistance to fluoroquinolones in Staphylococcus aureus.

Authors:  N Nakanishi; S Yoshida; H Wakebe; M Inoue; T Yamaguchi; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

5.  Modulation of gyrase-mediated DNA cleavage and cell killing by ATP.

Authors:  T K Li; L F Liu
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

6.  Characterization of mechanisms of quinolone resistance in Pseudomonas aeruginosa strains isolated in vitro and in vivo during experimental endocarditis.

Authors:  S Chamberland; A S Bayer; T Schollaardt; S A Wong; L E Bryan
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

7.  The effect of novobiocin on solvent production by Clostridium acetobutylicum.

Authors:  J Wong; G N Bennett
Journal:  J Ind Microbiol       Date:  1996-06

Review 8.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

9.  Comparative in vitro activities of a new quinolone, OPC-17116, possessing potent activity against gram-positive bacteria.

Authors:  H Wakebe; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

10.  Mechanisms of clinical resistance to fluoroquinolones in Enterococcus faecalis.

Authors:  N Nakanishi; S Yoshida; H Wakebe; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.